Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for inhibition of cholangiocarcinoma cells

Tae Won Kwak1,*
Hye Lim Lee2,*
Yeon Hui Song2
Chan Kim3
Jungsoo Kim2
Sol-Ji Seo2
Young-II Jeong2
Dae Hwan Kang2,4

1Medical Convergence Textile Center, Gyeongbuk, Republic of Korea; 2Biomedical Research Institute, Pusan National University Hospital, Pusan, Republic of Korea; 3Amogreentech Co. Ltd. Gyeonggi-do, Republic of Korea; 4Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Gyeongnam, Republic of Korea

*These authors contributed equally to this work

Purpose: The aim of this study was to fabricate a vorinostat (Zolinza™)-eluting nanofiber membrane-coated gastrointestinal (GI) stent and to study its antitumor activity against cholangiocarcinoma (CCA) cells in vitro and in vivo.

Methods: Vorinostat and poly(DL-lactide-co-glycolide) dissolved in an organic solvent was sprayed onto a GI stent to make a nanofiber-coated stent using an electro-spinning machine. Intact vorinostat and vorinostat released from nanofibers was used to assess anticancer activity in vitro against various CCA cells. The antitumor activity of the vorinostat-eluting nanofiber membrane-coated stent was evaluated using HuCC-T1 bearing mice.

Results: A vorinostat-incorporated polymer nanofiber membrane was formed on the surface of the GI stent. Vorinostat was continuously released from the nanofiber membrane over 10 days, and its release rate was higher in cell culture media than in phosphate-buffered saline. Released vorinostat showed similar anticancer activity against various CCA cells in vitro compared to that of vorinostat. Like vorinostat, vorinostat released from nanofibers induced acetylation of histone H4 and inhibited histone deacetylases 1,3,4,5/7 expression in vitro and in vivo. Furthermore, vorinostat nanofibers showed a higher tumor growth inhibition rate in HuCC-T1 bearing mice than vorinostat injections.

Conclusion: Vorinostat-eluting nanofiber membranes showed significant antitumor activity against CCA cells in vitro and in vivo. We suggest the vorinostat nanofiber-coated stent may be a promising candidate for CCA treatment.

Keywords: vorinostat, nanofiber, GI stent, cholangiocarcinoma, drug eluting

Introduction

Metal stents are used to maintain drainage when the gastrointestinal (GI) duct is blocked by tumor growth or inflammation.1-4 Cholangiocarcinoma (CCA), which is derived from the epithelium of the bile ducts, is frequently diagnosed at an advanced state and typically has a poor prognosis with a short median survival time.5-7 Palliative endoscopic stenting for advanced CCA is frequently conducted to prolong patient survival when curative options, such as surgical removal, is not possible.1,10 Covered or uncovered metal stents only provide mechanical palliation of the obstructed bile duct with absence of anticancer activity when biliary obstruction has occurred due to tumor growth.8,9 Drug-eluting stents (DESs) have been extensively investigated for the treatment of GI cancer, including CCA.10-14 Paclitaxel-eluting stents are known to have anti-tumor efficacy in rabbit esophageal squamous carcinoma models, ie, paclitaxel-eluting stents reduced the tumor area to a third of the metal stent.15 Kim et al also reported that paclitaxel-eluting stents inhibited CT26 colon tumor growth in a
mouse tumor xenograft model. In this report, they showed that the volume of tumors treated with paclitaxel-eluting membranes were more than 50% smaller than those treated with paclitaxel injection. Previously, we also reported that a sorafenib-eluting GI stent had anti-tumor efficacy against HuCC-T1 CCA cells in vitro and in animal tumor xenograft models. Anticancer agent-eluting stents for CCA may represent a prospective treatment option to prolong patient survival.

Suberoylanilide hydroxamic acid (Zolinza™ [vorinostat]), a zinc ion chelator that acts on the active site of histone deacetylases (HDACs), is a common HDAC inhibitor and regulates transcription through acetylation/deacetylation processes. Vorinostat is the first HDAC inhibitor approved by the US Food and Drug Administration for the treatment of cutaneous T cell lymphoma. Recent clinical trials demonstrated that vorinostat is a safe and effective treatment for GI cancer. Vorinostat has been reported to have inhibitory effects against various CCA cells in vitro and in vivo alone and in combination with other drugs.

Since nanofiber mats have a similar scale to biological interface and superior biocompatibility, they have been extensively investigated in the biomedical field. Due to these intrinsic properties, nanofibers have been applied in scaffold materials, biomedical devices, and drug delivery devices. Nanofibers have been explored as a drug delivery device for bioactive molecules because they have large surface areas and the small fiber thickness and drug release behavior can be easily controlled. These unique features of nanofibers make them a suitable device for drug-eluting membrane-covered GI stents.

In this study, we fabricated a nanofiber-coated GI stent for vorinostat-eluting stent development. Vorinostat-incorporated nanofibers were fabricated using an electro-spinning technique and simultaneously coated onto a GI stent. Their physicochemical properties, such as morphology and drug release behavior, were investigated. Furthermore, their anticancer activities against CCA cells were studied in vitro and in a tumor xenograft model.

## Materials and methods

### Materials

Poly(DL-lactide-co-glycolide) (PLGA 503H) was purchased from Evonik Co. Inc. (Darmstadt, Germany). Vorinostat was purchased from LC Laboratories® Co. (Woburn, MA, USA). Tetrahydrofuran (THF), acetone, and dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Silicon-membrane-covered stent for bile duct was purchased from M.I. Tech. (Pyeongtaek-si, Korea). Cell culture supplies such as RPMI 1640 media and fetal bovine serum (FBS) were purchased from ThermoFisher Scientific (Waltham, MA, USA). All reagent and organic solvents used were HPLC-grade.

### Fabrication of vorinostat-incorporated nanofiber membrane and coating of the GI stent

Vorinostat-incorporated nanofiber was coated onto a GI stent as shown in Figure 1. Vorinostat (50 mg) was dissolved in 0.5 mL THF/9.5 mL acetone solution. To this solution, 500 mg PLGA was then added and dissolved completely with magnetic stirring. This solution was coated onto a GI stent using an electro-spinning machine (EBS ES-Biocoater; Nano NC, Seoul, South Korea), consisting of a high-voltage power supply, syringe pump, X-Y robotic system, and drum-roll collector. The silicone-membrane-covered metal stent was placed into the rolling collector, and polymer/drug solution in a syringe (NanoNC, 24G) was sprayed onto the silicone-membrane-covered metal stent (diameter 1 cm, length 10 cm, rolling speed 500 rpm, spray rate 100 µL/minute, voltage 15 kV). Vorinostat-incorporated nanofiber membrane was coated onto the stent and then used as vorinostat nanofiber-coated stent. Any remaining solvent in the vorinostat nanofiber-coated stent was removed in a vacuum drying oven at room temperature for 24 h. The final products were stored at 4°C. For drug release studies and animal studies, vorinostat nanofiber membrane was carefully isolated from the stent and used.

Nanofiber membrane without vorinostat (empty nanofiber) was prepared using a similar method in the absence of vorinostat as described previously.

Drug contents and loading efficiency in the nanofibers were evaluated using an HPLC system as described previously. The Flexar HPLC system (Flexar HPLC system, PerkinElmer®, Waltham, MA, USA) was composed of a Solvent Manager 5-CH degasser, an autosampler, a quaternary LC pump, a column oven, and an UV/VIS detector. Chromatography was performed with a guard column (SecurityGuard® Guard Cartridge Kit; Phenomenex, Torrance, CA, USA) and a C18 column (Brownlee C18®, 5 µm, 150×4.6; PerkinElmer Inc., Waltham, MA, USA) at 37°C. Vorinostat was isocratically eluted from 10 mg vorinostat nanofibers using mobile phase (acetonitrile/0.1% formic acid at a ratio of 22/78); vorinostat was detected at 241 nm (flow rate of mobile phase: 1 mL/min). Recorded chromatograms were integrated with the Chromera 2.1 system software.
Drug content and loading efficiency of vorinostat in the nanofibers were calculated as follows:

\[
\text{Drug content} = \left(\frac{\text{Drug weight in the nanofiber}}{\text{Weight of nanofiber}}\right) \times 100
\]

\[
\text{Loading efficiency} = \left(\frac{\text{Residual drug in the nanofiber}}{\text{Initial feeding amount of drug}}\right) \times 100
\]

**Morphology**

Morphological observation of the nanofiber surface was examined with a field-emission scanning electron microscope (S-4800; Hitachi Co., Tokyo, Japan) at 25 kV.

**Drug release study**

Drug release was carried out using a phosphate-buffered saline (PBS, 10 mM, pH 7.4) solution at 37°C. A 20 mg nanofiber membrane was introduced into a falcon tube with 40 mL of PBS solution or RPMI 1640 media and placed in a shaking incubator (Multi Shaking Incubator, HB-201MS-4; Hanbaek Sci. Co., Bucheon-si, Korea) at 100 rpm. The released vorinostat was measured with an HPLC system as described previously.\(^\text{28}\) The equation of total released drug was as follows:

\[
\text{Total released drug} = \left(\frac{\text{Weight of released drug}}{\text{Total weight of drug in the nanofiber membrane}}\right) \times 100.
\]

For comparison, similar weight of empty nanofiber membrane was used as a control, and its media were used to measure drug concentration as a blank test.

**Cell culture**

The HuCC-T1 CCA cell line was received from the Health Science Research Resources Bank (Osaka, Japan). SNU478, SNU245, and SNU 1196 CCA cell lines were obtained from Korean Cell Line Bank (Seoul, Korea). Cells were maintained in RPMI 1640 supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin at 37°C in a 5% CO\(_2\) incubator.

**Anticancer activity study**

CCA cells (1×10\(^4\)) were seeded in 96-well plates to anticancer activity. Cells were incubated in a CO\(_2\) incubator
(37°C) overnight. Following this, vorinostat in DMSO or vorinostat released from nanofibers was diluted with RPMI 1640 media and applied to cells. The anticancer activity study was carried out with serum-free RPMI 1640 media. For control treatment, cells were treated with 0.5% (v/v) DMSO. For evaluation of anticancer activity of released vorinostat, vorinostat nanofibers (20 mg) were immersed in serum-free RPMI 1640 media; vorinostat was eluted from nanofibers as described previously. One and 2 days later, supernatants of the media were diluted with serum-free RPMI 1640 media and added to cells. The concentration of eluted vorinostat was measured as described previously. Cell viability was assessed with the MTT proliferation assay. Twenty-four or 48 h later, 25 µL MTT (5 mg/mL PBS, pH 7.4) solution was added to the cells, and the cells were further incubated for 4 h. The medium was then removed, and 100 µL DMSO was added to each well. This was gently shaken for 10 min. Cell viability was measured with an Infinite M200 Pro microplate reader (Tecan, Mannndorf, Switzerland) at 570 nm. Viability was expressed as mean ± standard deviation from eight wells.

Apoptosis and necrosis analysis

Cells seeded in 6-well plates (1×10⁶ cells per well) were treated with various concentrations of vorinostat released from vorinostat nanofibers and then incubated in a CO₂ incubator overnight. For evaluation of drug stability in nanofibers, vorinostat was released from nanofibers using serum-free RPMI media for 1 day, 5 days, and 7 days. After that, vorinostat released from nanofibers was applied to cells for 1 day. The cells were harvested by trypsinization, washed with PBS, and suspended in 500 µL of binding buffer. Cells were stained with FITC-conjugated Annexin V for the apoptosis assay and with propidium iodide (PI) for the necrosis analysis. Apoptosis and necrosis were analyzed by flow cytometry (BD Biosciences, San Jose, CA, USA).

Western blotting

Western blotting of CCA cells was performed as described previously.²⁸ Cells treated for 24 h with vorinostat or vorinostat released from nanofibers were harvested by trypsinization, washed with cold PBS, and collected by centrifugation. Pellets were lysed in lysis buffer containing 50 mM Tris, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulfate (SDS) with phenylmethylsulfonyl fluoride, and a protease inhibitor cocktail (Roche Diagnostics GmbH, Roche Applied Sci., Mannheim, Germany). This solution was centrifuged for 30 min at 4°C (14,000× g); the cell lysates (supernatant) were then used to measure protein concentration using the BCA Protein Assay kit (Pierce, Rockford, IL, USA). Protein (50 µg) was loaded into SDS-polyacrylamide gel electrophoresis, transferred to a polyvinyl difluoride membrane, blocked with 5% skim milk in TBS-T, probed with an appropriate primary antibody, and then treated with a secondary HRP-conjugated antibody for 1 h. The immunoblots were detected by chemiluminescence and then quantified with digital analyses using the ImageJ software program.

Antitumor activity of vorinostat-incorporated nanofiber in the animal tumor xenograft model

Antitumor activity of vorinostat-incorporated nanofiber-coated stent was assessed with HuCC-T1-bearing nude mice. HuCC-T1 cells (1×10⁶) in 100 µL of PBS were subcutaneously (s.c.) injected into the backs of nude mice (5 weeks old, male, 20–25 g in weight; Orient, Seongnam, South Korea). When the tumor size reached approximately 4 mm in diameter, an empty nanofiber and vorinostat-incorporated nanofiber were implanted under the solid tumor. The treatment dose was adjusted to 10 mg vorinostat/kg. Mice were divided into four groups: control (untreated) group, PBS was s.c. injected beside tumor tissue; vorinostat injection group, vorinostat solution was s.c. injected beside tumor tissue (vorinostat dose: 10 mg/kg); empty nanofiber group, an empty nanofiber was implanted under the solid tumor; vorinostat nanofiber group, a vorinostat-incorporated nanofiber was implanted under the solid tumor (vorinostat dose, 10 mg/kg). For vorinostat injection, vorinostat was dissolved in ethanol/Cremophor EL® (1/1) mixed solution and then diluted ten times with PBS. For empty nanofiber and vorinostat nanofiber implantation, wafers of the same weight were cut and then implanted under the tumor tissue. For implantation of empty or vorinostat nanofibers, skin from the back of the mouse was excised (0.5 cm in length). For comparison, skin from control treatment and vorinostat injected mice were also excised (0.5 cm in length). Each group consisted of four mice. Tumor volume was measured at 2–5-day intervals, and the first day of treatment was Day 0. Tumor volume was calculated with the following equation:

\[ V = \frac{a \times b^2}{2}. \]

\( a \): largest diameter; \( b \): smallest diameter.

All of the animal studies were conducted strictly according to the guidelines of the Pusan National University Institutional Animal Care and Use Committee (PNUIACUC). The animal protocol used in this study has been reviewed by...
the PNUIACUC in terms of ethical procedures and scientific care, and approved (approval number: PNU-2017-1608).

**Immunohistochemistry**

Solid tumors were isolated 26 days later and fixed in 4% formaldehyde. Tumor tissues were then paraffin-embedded and sliced for H and E staining. Immunohistochemical staining was carried out with acetyl histone H3 antibody at a dilution of 1:500, HDAC1 antibody at a dilution of 1:100, and HDAC3/HDAC4 antibodies at a dilution of 1:200. Staining was performed using an Envision kit (Thermo-Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol.

**Statistical analysis**

Statistical analyses of the data from treated and untreated cells were performed using Student’s t-test. A p-value \(< 0.05\) was considered to be statistically significant.

**Results**

**Characterization of vorinostat nanofiber-coated stent**

Vorinostat-incorporated nanofibers were coated onto a covered GI stent with an electro-spinning technique as shown in Figure 1. To adhere vorinostat-incorporated nanofibers onto the GI stent, a silicone-membrane-covered stent was used, and polymer/vorinostat solution was sprayed onto the covered GI stent (Figure 1A). As shown in Figure 1B, an empty nanofiber and vorinostat-incorporated nanofiber were fabricated successfully. Vorinostat nanofibers have more granules or particles in their structure compared to empty nanofibers, even though the fiber thickness of vorinostat nanofibers seem to be smaller than empty nanofibers (Figure 1B). Fiber diameters of both empty and vorinostat nanofibers were less than 1 \(\mu\)m. Figure 1C shows a schematic illustration of vorinostat release from vorinostat nanofibers in the bile duct region. Vorinostat nanofibers coated onto the silicone membrane-covered stent would have been in direct contact with tumor tissues. The silicone membrane on the metal stent blocked the loss of drug into the luminal space, allowing vorinostat to be efficiently delivered to the tumor tissue with minimal drug loss.

Drug contents and loading efficiency were \(-9.0\% (w/w)\) and 98.8%, respectively. Drug contents between theoretical and experimental values were not significantly different, and most of the drug was successfully incorporated into nanofibers.

Drug release experiments were performed in PBS solution or cell culture media (RPMI 1640 media) as shown in Figure 2. Vorinostat nanofibers showed initial burst release for 8 h in cell culture media and 24 h in PBS solution. When cell culture media were adapted to the drug release study as shown in Figure 2A, the vorinostat release rate was very fast and almost all of the drug was liberated by 4 days. These results might be due to various nutrients in the cell culture media, such as salt, vitamin, or protein, that act as a surfactant and facilitated solubilization of vorinostat. The vorinostat release rate was relatively slow in PBS solution, and vorinostat was released over 10 days due to the hydrophobicity of vorinostat.

**Anticancer activity in vitro**

The vorinostat nanofiber-coated stent was assessed with CCA cells, including HuCC-T1, SNU478, SNU245, and SNU1196. Vorinostat dissolved in DMSO or vorinostat

![Figure 2](https://www.dovepress.com/...)

**Notes:** (A) RPMI 1640 media supplemented with 10% FBS and antibiotics; (B) PBS solution.

**Abbreviations:** FBS, fetal bovine serum; PBS, phosphate-buffered saline.
released from nanofibers was diluted with cell culture media and then added to cells. Cell viability is shown in Figures 3 and 4. As shown in Figure 3, CCA cell viability was dose-dependently decreased according to vorinostat concentration. Vorinostat released from nanofibers showed similar anticancer efficacy to vorinostat itself, indicating that the intrinsic anticancer activity of vorinostat was not changed during the nanofiber fabrication process.

Figure 4 shows the effect of the vorinostat release period from nanofibers on the anticancer activity against HuCC-T1 and SNU478 cells in vitro. Vorinostat released from nanofibers at 1 day, 3 days, 5 days, and 7 days was used to assess anticancer activity and apoptosis/necrosis analysis against SNU478 and HuCC-T1 cells. As shown in Figure 4A, cell viability in vorinostat released from nanofibers was not significantly changed compared to vorinostat itself, the drug maintained anticancer activity after 7 days of the drug release experiment. Apoptosis/necrosis analysis also supported these results, as shown in Figure 4B. The number of apoptotic/necrotic cells was not significantly changed between Days 1, 5, and 7 of the drug release period compared to vorinostat itself. These results indicated that the intrinsic biological activity of vorinostat is maintained during the nanofiber fabrication process and drug release period.

Figure 5 shows the results of Western blotting of HuCC-T1 cells after treatment with vorinostat, empty nanofiber, and vorinostat nanofiber. To assess vorinostat activity in nanofibers, a vorinostat nanofiber was dissolved in DMSO and vorinostat released in media from nanofiber (Figure 2) was harvested. This solution was added to cells. As shown in Figure 5, expression of Ac-histone H3 and H4 was shown as a strong band when vorinostat was applied to HuCC-T1

Figure 3 Anticancer activity of vorinostat and vorinostat released from nanofibers against various CCA cells.

Notes: (A) HuCC-T1, (B) SNU478, (C) SNU 1196, and (D) SNU245 CCA cells; 1×10^4 cells in 96-well plates were exposed to vorinostat or vorinostat released from nanofibers for 2 days.

Abbreviation: CCA, cholangiocarcinoma.
Figure 4 The effect of vorinostat and released vorinostat against HuCC-T1 and SNU478 cells.

**Notes:** (A) Anticancer activity and (B) apoptosis/necrosis analysis. The supernatants were taken at 1 day, 3 days, 5 days, and 7 days of release experiment as described in experimental section. These solutions were used for released vorinostat treatment.

**Abbreviation:** PI, propidium iodide.

cells. Furthermore, HuCC-T1 cells showed decreased HDAC 1, 2, 3, and 4/5/7 expression after treatment of vorinostat. Both vorinostat dissolved in DMSO and vorinostat released in media also showed increased Ac-histone H3/Ha and decreased HDAC 1-2-3-4/5/7 when added to cells. These results indicated that the intrinsic anticancer activity of vorinostat was maintained during the process of nanofiber fabrication and drug release study. Also, these results enabled us to predict anticancer activity of vorinostat nanofiber in vivo study.

**Anticancer activity in vivo**

To assess anticancer activity of vorinostat nanofiber in vivo, a solid tumor xenograft was prepared by implantation of HuCC-T1 cells into the back of mice as shown in Figure 6. As shown in Figure 6, tumor volume of tumors treated with vorinostat nanofiber was noticeably smaller than those receiving control treatment, vorinostat injection or empty nanofiber, indicating that vorinostat in nanofiber was released continuously to tumor tissue and suppressed growth of solid tumors. Furthermore, expression of Ac-histone H4 was increased...
Figure 5 Western blot analysis of Ac-histone H3, H4, and HDACs' expression in HuCC-T1 cells.
Abbreviation: HDACs, histone deacetylases.

Figure 6 Antitumor activity of vorinostat-eluting nanofibers in HuCC-T1 cell-bearing mice.
Notes: (A) Changes of tumor volume. (B) Body weight at 22 days. *P<0.05. Vorinostat dose: 10 mg/kg. PBS or vorinostat solution was s.c. injected beside tumor tissue for control (untreated) and vorinostat injection group, respectively. For empty nanofiber and vorinostat nanofiber implantation, wafers of the same weight were cut and then implanted under the tumor tissue.
Abbreviations: PBS, phosphate-buffered saline; s.c., subcutaneously; NF, nanofiber.
with treatment of vorinostat nanofiber compared to control, vorinostat injection or empty nanofiber treatment, as shown in Figure 7. HDAC 1, 3, and 4/5/7 expression also decreased with treatment of vorinostat nanofiber, while control, vorinostat injection, and empty nanofiber showed increased HDAC expression. These results indicated that vorinostat nanofibers are effective in increasing acetylation of histone and suppressing HDAC expression. Therefore, vorinostat nanofiber inhibited CCA cells in vitro and in vivo.

**Discussion**

CCA is regarded as one of the most aggressive cancers, because patients with CCA are frequently diagnosed at an advanced stage with a median survival time of less than 24 months.\(^{29,30}\) Although surgical removal is generally considered as the best treatment option to prolong patient survival, less than one third of diagnosed CCA tumors can be surgically resected.\(^{30}\) For unresectable CCA, conventional chemotherapy or radiotherapy can be considered as treatment option,\(^ {30,31}\) however, these treatment options offer limited clinical benefit for the management of CCA patients. Placement of a metal stent for CCA patients is a palliative treatment option to maintain drainage of the bile duct and to prolong survival time.\(^ {1,4}\) In terms of anticancer functionality, anticancer agent-eluting GI stents have been extensively investigated during the last decade.\(^ {10-13,32-34}\) Paclitaxel-eluting stents for biliary obstruction have been developed for human application.\(^ {32-34}\) Lee et al have reported safety issues related to...
to anticancer agent-eluting stents used in a porcine model. They demonstrated the biological safety of DES and usefulness in local delivery of anticancer agent. Suk et al reported that the paclitaxel-eluting stent has feasibility, safety, and effectiveness as treatment for malignant biliary obstruction; however, the paclitaxel-eluting stent needs to be improved significantly in terms of anticancer efficacy and patency, because the paclitaxel-eluting stent showed negligible differences in stent patency and patient survivability compared to that of metal stents. We previously reported the anticancer efficacy of the sorafenib-eluting stent for CCA cells. Sorafenib effectively inhibited proliferation and migration of CCA cells in vitro and in vivo. Sorafenib was continuously released over 1 month, and anticancer activity was maintained for 30 days. In a tumor xenograft model using HuCC-T1 cells, the sorafenib-eluting stent effectively suppressed the tumor growth compared to control treatment.

Nanoscale materials such as nanoparticles, nanofibers, and polymeric conjugates are also highlighted in the application of DES. Among them, nanofiber mats are regarded as an ideal candidate for DES. Nanofibers have a unique microenvironment structure similar to that of a biological surface, easy to control drug release rate, and availability to incorporate various bioactive agents. Compared to other kinds of drug-eluting devices such as nanoparticles or microspheres, nanofiber mats provide a uniform coating layer on the GI stent; a simple coating process, ie, nanofiber mats can be coated onto GI stents by a one-step process using an electro-spinning machine, while nanoparticles or microspheres need to be separated from the dispersed solution with an additional process for stent coating. Furthermore, the malleable nature of nanofiber mats is essential for stent application, making them suitable devices for DES. Many investigators have evaluated nanofibers as a drug delivery device compared to nanoparticles. For example, Shan et al reported that nanofibers of methoxy poly(ethylene glycol)-poly lactic acid copolymer provide better zero-order release kinetics of drugs, while burst drug release was observed from nanoparticles. For these reasons, drug-eluting nanofibers have received attention from many research groups for application in DES. Kim et al reported that a paclitaxel-eluting nanofiber-covered stent effectively inhibited colon cancer cells and extended stent patency. We also previously reported that a photosensitizer-eluting nanofiber-coated stent has efficacy against CCA cells. Vorinostat-incorporated nanofibers can be simply coated onto a covered stent (Figure 1) with an electro-spinning technique. This demonstrated the sustained release characteristics of vorinostat, as shown in Figure 2. Interestingly, vorinostat release behavior was significantly changed by media; most of the vorinostat was released over 4 days when RPMI 1640 cell culture media were used for drug release. The release rate of vorinostat was very slow, however, in PBS solution.

The dominant mechanism of vorinostat release behavior might be diffusion of drugs into media; however, vorinostat release must be principally governed by a polymer degradation mechanism, because PLGA nanofibers with a 50:50 lactide:glycolide ratio is known to degrade linearly for up to 100 days. In that report, Dong et al also reported that the half-life of PLGA degradation was 80 days. In other reports, more than 30% of the molecular weight of PLGA (50:50, lactide:glycolide ratio) degraded for 30 days. Vorinostat release rate in PBS might be governed by degradation of polymers, except the period of initial burst of vorinostat.

Vorinostat nanofibers effectively inhibited the growth of HuCC-T1 tumors in a mouse xenograft model (Figure 6). Vorinostat released from nanofiber inhibited HDAC expression and induced acetylation of histone H3/H4 in vitro and in vivo (Figures 5 and 7). We previously reported that vorinostat-incorporated nanoparticles have higher efficacy in suppression of tumor growth and induction of Ac-histone with suppression of HDAC protein compared to vorinostat itself, because vorinostat-incorporated nanoparticles remained in tumor tissue longer. In this study, vorinostat released from nanofibers was similar in acetylation of histone H3/H4 and suppression of HDAC 1:2:3:4:5/7 compared to vorinostat itself (Figures 5 and 7). Since HDAC expression of CCA cells is closely related to advanced stage and poor prognosis, inhibition of its expression is a potential treatment candidate to prolong patient survivability. Furthermore, Boonjaraspinyo et al found that HDAC6 expression has a significant relationship with the stage of CCA. Gradilone et al also reported that HDAC6 inhibition induced a significant decrease in tumor growth. Although we did not show HDAC6 expression, vorinostat nanofibers showed positive results in inhibition of HDAC expression and induction of Ac-histone. These favorable results encourage future preclinical study and clinical feasibility.

**Conclusion**

In conclusion, we fabricated vorinostat nanofibers using biodegradable polymers with an electro-spinning technique. Vorinostat-incorporated nanofiber membrane was properly coated on the GI stent and formed nanofiber mats. Vorinostat was released from the nanofiber membrane over 1 week. Released vorinostat showed similar anticancer activity against...
various CCA cells in vitro compared to intact vorinostat. Like intact vorinostat, vorinostat released from nanofibers induced acetylation of histone H3/H4 and inhibited HDAC 1-2-3-4/5/7 expression in vitro and in vivo. Furthermore, vorinostat nanofibers showed higher inhibition of tumor growth in HuCC-T1 tumor-bearing mice. We suggest that vorinostat nanofibers are a promising candidate for CCA treatment.

Acknowledgment
This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (project no H114C2220).

Disclosure
The authors report no conflicts of interest in this work.

References


